interaction mechanism. Modify Therapy/Monitor Closely. Coadministration of ferric maltol with certain oral medications may decrease the bioavailability of either ferric maltol and some oral drugs. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate administration of ferric maltol from these drugs. Duration of separation may depend on the absorption of the medication concomitantly administered (eg, time to peak concentration, whether the drug is an immediate or extended release product).fexinidazoleSerious - Use Alternative (1)fexinidazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fleroxacinMinor (1)fleroxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.flibanserinMonitor Closely (1)triazolam and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.fluconazoleMonitor Closely (1)fluconazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fludrocortisoneMonitor Closely (1)fludrocortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fluphenazineMonitor Closely (1)triazolam and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamMonitor Closely (1)flurazepam and triazolam both increase sedation. Use Caution/Monitor.fluvoxamineMonitor Closely (1)fluvoxamine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.formoterolMonitor Closely (1)triazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fosamprenavirMonitor Closely (1)fosamprenavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fosamprenavir increases levels of triazolam by decreasing metabolism. Contraindicated.fosaprepitantMonitor Closely (1)fosaprepitant will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.gabapentinMonitor Closely (1)gabapentin, triazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, triazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxoloneMonitor Closely (1)triazolam and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMinor (1)gemifloxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.glofitamabMonitor Closely (1)glofitamab, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .glycerol phenylbutyrateMonitor Closely (1)glycerol phenylbutyrate will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index.grapefruitMonitor Closely (1)grapefruit will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.griseofulvinMonitor Closely (1)griseofulvin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.haloperidolMonitor Closely (1)triazolam and haloperidol both increase sedation. Use Caution/Monitor.hydrocodoneSerious - Use Alternative (1)hydrocodone, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydrocortisoneMonitor Closely (1)hydrocortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.hydromorphoneMonitor Closely (1)triazolam and hydromorphone both increase sedation. Use Caution/Monitor.hydroxyzineMonitor Closely (1)hydroxyzine and triazolam both increase sedation. Use Caution/Monitor.idelalisibSerious - Use Alternative (1)idelalisib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesiloperidoneMonitor Closely (2)iloperidone increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4. triazolam and iloperidone both increase sedation. Use Caution/Monitor.imipramineMonitor Closely (1)triazolam and imipramine both increase sedation. Use Caution/Monitor.indinavirMonitor Closely (1)indinavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)indinavir increases levels of triazolam by decreasing metabolism. Contraindicated.isavuconazonium sulfateMonitor Closely (1)isavuconazonium sulfate will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoniazidMonitor Closely (1)isoniazid will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoproterenolMonitor Closely (1)triazolam increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.istradefyllineMonitor Closely (1)istradefylline will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleContraindicated (2)itraconazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Both drugs will increase QT interval itraconazole increases levels of triazolam by decreasing metabolism. Contraindicated.ivosidenibSerious - Use Alternative (1)ivosidenib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.ketamineMonitor Closely (1)ketamine and triazolam both increase sedation. Use Caution/Monitor.ketoconazoleContraindicated (1)ketoconazole increases levels of triazolam by decreasing metabolism. Contraindicated.ketotifen, ophthalmicMonitor Closely (1)triazolam and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lapatinibMonitor Closely (1)lapatinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.larotrectinibMonitor Closely (1)larotrectinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lasmiditanMonitor Closely (1)lasmiditan, triazolam. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantSerious - Use Alternative (1)lemborexant, triazolam. Either increases effects of the other by sedation. Avoid or Use Alternate Drug. Use of lemborexant with other drugs to treat insomnia is not recommended.lenacapavirMonitor Closely (1)lenacapavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.levalbuterolMonitor Closely (1)triazolam increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacinMinor (1)levofloxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.levoketoconazoleContraindicated (2)levoketoconazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. levoketoconazole increases levels of triazolam by decreasing metabolism. Contraindicated.levonorgestrel oral/ethinylestradiol/ferrous bisglycinateMonitor Closely (1)levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of triazolam by decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines.levorphanolMonitor Closely (1)triazolam and levorphanol both increase sedation. Use Caution/Monitor.lisdexamfetamineMonitor Closely (1)triazolam increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lofepramineMonitor Closely (1)triazolam and lofepramine both increase sedation. Use Caution/Monitor.lofexidineMonitor Closely (1)triazolam and lofexidine both increase sedation. Use Caution/Monitor.lonafarnibSerious - Use Alternative (1)lonafarnib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.lonapegsomatropinMonitor Closely (1)lonapegsomatropin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substrateslopinavirContraindicated (1)lopinavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.loprazolamMonitor Closely (1)loprazolam and triazolam both increase sedation. Use Caution/Monitor.lorazepamMonitor Closely (1)lorazepam and triazolam both increase sedation. Use Caution/Monitor.lorlatinibSerious - Use Alternative (1)lorlatinib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid use of lorlatinib with CYP3A substrates, where minimal concentration changes may lead to serious therapeutic failures of the substrate. If concomitant use is unavoidable, increase CYP3A substrate dosage in accordance with approved product labeling.lormetazepamMonitor Closely (1)lormetazepam and triazolam both increase sedation. Use Caution/Monitor.loxapineMonitor Closely (1)triazolam and loxapine both increase sedation. Use Caution/Monitor.loxapine inhaledMonitor Closely (1)triazolam and loxapine inhaled both increase sedation. Use Caution/Monitor.lumacaftor/ivacaftorSerious - Use Alternative (1)lumacaftor/ivacaftor will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Lumacaftor is a strong inducer of CYP3A. Avoid coadministration with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index.lumefantrineMonitor Closely (1)lumefantrine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lurasidoneMonitor Closely (1)lurasidone, triazolam. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilineMonitor Closely (1)triazolam and maprotiline both increase sedation. Use Caution/Monitor.marijuanaMonitor Closely (2)marijuana will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. triazolam and marijuana both increase sedation. Use Caution/Monitor.melatoninMonitor Closely (1)triazolam and melatonin both increase sedation. Use Caution/Monitor.meperidineMonitor Closely (1)triazolam and meperidine both increase sedation. Use Caution/Monitor.meprobamateMonitor Closely (1)triazolam and meprobamate both increase sedation. Use Caution/Monitor.metaproterenolMonitor Closely (1)triazolam increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxaloneMonitor Closely (1)triazolam and metaxalone both increase sedation. Use Caution/Monitor.methadoneMonitor Closely (1)triazolam and methadone both increase sedation. Use Caution/Monitor.methamphetamineMonitor Closely (1)triazolam increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamolMonitor Closely (1)triazolam and methocarbamol both increase sedation. Use Caution/Monitor.methylenedioxymethamphetamineMonitor Closely (1)triazolam increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylprednisoloneMonitor Closely (1)methylprednisolone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.metoclopramide intranasalSerious - Use Alternative (1)triazolam, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.metronidazoleMonitor Closely (1)metronidazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.miconazole vaginalMonitor Closely (1)miconazole vaginal will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.midazolamMonitor Closely (1)midazolam and triazolam both increase sedation. Use Caution/Monitor.midazolam intranasalMonitor Closely (1)midazolam intranasal, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrineMonitor Closely (1)triazolam increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mifepristoneContraindicated (1)mifepristone will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.mirtazapineMonitor Closely (1)triazolam and mirtazapine both increase sedation. Use Caution/Monitor.mitotaneMonitor Closely (1)mitotane decreases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.mobocertinibSerious - Use Alternative (1)mobocertinib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, increase CYP3A4 substrate dosage in accordance with its prescribing information.modafinilMonitor Closely (1)triazolam increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphineMonitor Closely (1)triazolam and morphine both increase sedation. Use Caution/Monitor.motherwortMonitor Closely (1)triazolam and motherwort both increase sedation. Use Caution/Monitor.moxifloxacinMinor (1)moxifloxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.moxonidineMonitor Closely (1)triazolam and moxonidine both increase sedation. Use Caution/Monitor.nabiloneMonitor Closely (1)triazolam and nabilone both increase sedation. Use Caution/Monitor.nalbuphineMonitor Closely (1)triazolam and nalbuphine both increase sedation. Use Caution/Monitor.nefazodoneSerious - Use Alternative (1)nefazodone will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate